Insider Transactions in Q1 2022 at Bristol Myers Squibb CO (BMY)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2022
|
Giovanni Caforio Executive Chair of the Board |
SELL
Bona fide gift
|
Direct |
420
-0.07%
|
-
|
|
Mar 21
2022
|
Giovanni Caforio Executive Chair of the Board |
SELL
Open market or private sale
|
Direct |
25,000
-4.12%
|
$1,775,000
$71.52 P/Share
|
|
Mar 16
2022
|
Rupert Vessey EVP & President, Research |
SELL
Open market or private sale
|
Direct |
74,559
-43.27%
|
$5,144,571
$69.25 P/Share
|
|
Mar 16
2022
|
Rupert Vessey EVP & President, Research |
BUY
Exercise of conversion of derivative security
|
Direct |
47,305
+12.9%
|
$2,507,165
$53.64 P/Share
|
|
Mar 14
2022
|
Christopher S. Boerner Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
29,532
-41.3%
|
$2,037,708
$69.2 P/Share
|
|
Mar 14
2022
|
Karen Murphy Santiago SVP & Controller |
SELL
Open market or private sale
|
Direct |
6,577
-28.25%
|
$453,813
$69.19 P/Share
|
|
Mar 10
2022
|
Elizabeth Mily EVP, Strategy & BD |
SELL
Payment of exercise price or tax liability
|
Direct |
1,875
-21.56%
|
$127,500
$68.42 P/Share
|
|
Mar 10
2022
|
Elizabeth Mily EVP, Strategy & BD |
BUY
Other acquisition or disposition
|
Direct |
449
+4.91%
|
-
|
|
Mar 10
2022
|
Elizabeth Mily EVP, Strategy & BD |
BUY
Exercise of conversion of derivative security
|
Direct |
4,005
+32.69%
|
-
|
|
Mar 10
2022
|
Rupert Vessey EVP & President, Research |
SELL
Payment of exercise price or tax liability
|
Direct |
8,751
-5.48%
|
$595,068
$68.42 P/Share
|
|
Mar 10
2022
|
Rupert Vessey EVP & President, Research |
BUY
Other acquisition or disposition
|
Direct |
1,859
+1.15%
|
-
|
|
Mar 10
2022
|
Rupert Vessey EVP & President, Research |
BUY
Exercise of conversion of derivative security
|
Direct |
15,247
+8.81%
|
-
|
|
Mar 10
2022
|
Karen Murphy Santiago SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
6,223
-5.29%
|
$423,164
$68.42 P/Share
|
|
Mar 10
2022
|
Karen Murphy Santiago SVP & Controller |
BUY
Other acquisition or disposition
|
Direct |
3,933
+2.87%
|
-
|
|
Mar 10
2022
|
Karen Murphy Santiago SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
11,073
+9.08%
|
-
|
|
Mar 10
2022
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
5,205
-14.48%
|
$353,940
$68.42 P/Share
|
|
Mar 10
2022
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
BUY
Other acquisition or disposition
|
Direct |
1,101
+2.99%
|
-
|
|
Mar 10
2022
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
9,074
+20.65%
|
-
|
|
Mar 10
2022
|
Ann Powell EVP, Chief Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
20,369
-5.47%
|
$1,385,092
$68.42 P/Share
|
|
Mar 10
2022
|
Ann Powell EVP, Chief Human Resources |
BUY
Other acquisition or disposition
|
Direct |
12,546
+2.83%
|
-
|
|
Mar 10
2022
|
Ann Powell EVP, Chief Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
35,686
+9.07%
|
-
|
|
Mar 10
2022
|
David V Elkins EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,222
-3.47%
|
$627,096
$68.42 P/Share
|
|
Mar 10
2022
|
David V Elkins EVP, Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
1,962
+0.73%
|
-
|
|
Mar 10
2022
|
David V Elkins EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,067
+5.74%
|
-
|
|
Mar 10
2022
|
Christopher S. Boerner Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
34,545
-9.65%
|
$2,349,060
$68.42 P/Share
|
|
Mar 10
2022
|
Christopher S. Boerner Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,417
+6.63%
|
-
|
|
Mar 10
2022
|
Christopher S. Boerner Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,715
+13.03%
|
-
|
|
Mar 10
2022
|
Christopher S. Boerner Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
2,399
+1.65%
|
-
|
|
Mar 10
2022
|
Sandra Leung EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
44,901
-2.34%
|
$3,053,268
$68.42 P/Share
|
|
Mar 10
2022
|
Sandra Leung EVP, General Counsel |
BUY
Other acquisition or disposition
|
Direct |
18,288
+0.9%
|
-
|
|
Mar 10
2022
|
Sandra Leung EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
60,273
+3.04%
|
-
|
|
Mar 10
2022
|
Giovanni Caforio Executive Chair of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
158,890
-5.1%
|
$10,804,520
$68.42 P/Share
|
|
Mar 10
2022
|
Giovanni Caforio Executive Chair of the Board |
BUY
Other acquisition or disposition
|
Direct |
72,458
+2.06%
|
-
|
|
Mar 10
2022
|
Giovanni Caforio Executive Chair of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
239,501
+7.21%
|
-
|
|
Mar 01
2022
|
David V Elkins EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,381
-7.86%
|
$705,908
$68.63 P/Share
|
|
Mar 01
2022
|
David V Elkins EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,577
+15.69%
|
-
|
|
Mar 01
2022
|
Rupert Vessey EVP & President, Research |
SELL
Payment of exercise price or tax liability
|
Direct |
10,303
-12.95%
|
$700,604
$68.63 P/Share
|
|
Mar 01
2022
|
Rupert Vessey EVP & President, Research |
BUY
Exercise of conversion of derivative security
|
Direct |
23,350
+22.68%
|
-
|
|
Feb 24
2022
|
Giovanni Caforio Executive Chair of the Board |
SELL
Open market or private sale
|
Direct |
30,000
-6.21%
|
$2,010,000
$67.0 P/Share
|
|
Feb 04
2022
|
Rupert Vessey EVP & President, Research |
SELL
Payment of exercise price or tax liability
|
Direct |
1,312
-2.28%
|
$83,968
$64.99 P/Share
|
|
Feb 04
2022
|
Rupert Vessey EVP & President, Research |
BUY
Exercise of conversion of derivative security
|
Direct |
3,593
+5.88%
|
-
|